INTERNATIONAL BIOTECHNOLOGY TRUST PLC
Portfolio Update as at 30 June 2016
|
Net Assets |
£202m |
|
Net Assets per share |
532p |
|
Share price |
458p |
|
Total value of unquoted investments |
£24m |
|
Total number of portfolio companies |
86 |
Top Ten Holdings
|
Company Name |
% NAV |
|
Biogen |
7.4 |
|
Celgene |
6.7 |
|
Genmab |
6.0 |
|
Regeneron |
5.0 |
|
Amgen |
4.4 |
|
Alexion |
4.4 |
|
Vertex |
3.5 |
|
Biomarin |
3.2 |
|
Actelion |
3.1 |
|
Intercept |
2.9 |
|
|
----------- |
|
Total |
46.6 |
|
Geographical Allocation |
% NAV |
|
US & Canada |
77 |
|
Europe & UK |
23 |
|
|
----------- |
|
Total |
100 |
|
Quoted/Unquoted Allocation |
% NAV |
|
Quoted |
89 |
|
Unquoted |
11 |
|
|
----------- |
|
Total |
100 |
|
NAV % Market Cap |
% NAV |
|
Large Cap >USD10BN |
68 |
|
Small Cap <USD1BN |
26 |
|
Mid Cap =USD1-10BN |
6 |
|
|
----------- |
|
Total |
100 |
|
NAV % by Therapeutic Areas |
% NAV |
|
Oncology |
38 |
|
Orphan |
20 |
|
CNS |
10 |
|
Other |
10 |
|
Inflammation |
9 |
|
Ophthalmology |
8 |
|
Medtech |
5 |
|
|
----------- |
|
Total |
100 |
BNP Paribas Secretarial Services Limited
Company Secretary
20 JULY 2016